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Abstract
This study aimed to determine the clinical course of patients and the quality of antibiotic use using a systematic and unsolicited post-
prescription antibiotic review. Seven hundred and ﬁfty-three adult patients receiving antibiotic therapy for 3–5 days were randomized to
receive either a post-prescription review by the infectious disease physician (IDP), followed by a recommendation to the attending physician
to modify the prescription when appropriate, or no systematic review of the prescription. In the intervention group, 63.3% of prescriptions
prompted IDP recommendations, which were mostly followed by ward physicians (90.3%). Early antibiotic modiﬁcations were more
frequent in the intervention group (57.1% vs. 25.7%, p <0.0001), including stopping therapy, shortening duration and de-escalating broad-
spectrum antibiotics. IDP intervention led to a signiﬁcant reduction of the median [IQR] duration of antibiotic therapy (6 [4–9] vs. 7 days
[5–9], p <0.0001). In-hospital mortality, ICU admission and new course of antibiotic therapy rates did not differ between the two groups.
Fewer patients in the intervention group were readmitted for relapsing infection (3.4% vs. 7.9%, p 0.01). There was a trend for a shorter
length of hospital stay in patients suffering from community-acquired infections in the intervention group (5 days [3–10] vs. 6 days [3–14],
p 0.06). This study provides clinical evidence that a post-prescription antibiotic review followed by unsolicited IDP advice is effective in
reducing antibiotic exposure of patients and increasing the quality of antibiotic use, and may reduce hospital stay and relapsing infection
rates, with no adverse effects on other patient outcomes.
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Abstract
Few data are available on treatment and outcome of methicillin-resistant (MR) staphylococcal prosthetic joint infections. Vancomycin
remains the treatment of choice for these infections, but its efﬁcacy and safety in bone-and-joint infections are insufﬁciently documented.
We conducted a prospective cohort study on 60 patients treated between November 2002 and December 2008 for chronic MR
staphylococcal (44 S. epidermidis, nine other coagulase-negative Staphylococcus and seven S. aureus) prosthetic hip infections (PHIs). Twenty-
two patients had previously undergone surgery for their PHI and 21 had previously received antibiotics. All patients had surgery (exchange
arthroplasty for 58 patients, resection arthroplasty for two) and received an antibiotic regimen combining high-dose continuous intravenous
vancomycin infusion (target serum concentration 30–40 mg/L) with another antibiotic for 6 weeks, followed by an additional 6 weeks of
oral intake. Two years after surgery, infection was considered cured in 41 (68%) patients and only two relapses occurred after one-stage
exchange arthroplasty. Nineteen (32%) patients experienced nephrotoxicity that was generally mild (RIFLE class R for 14 patients, class I for
four patients and class F for one patient) and most often reversible. Continuous high-dose intravenous vancomycin combination therapy is
an effective, feasible and reasonably safe treatment of chronic MR staphylococcal PHI.
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Abstract
Due to molecular mimicry, Campylobacter jejuni lipo-oligosaccharides can induce a cross-reactive antibody response to nerve gangliosides,
which leads to Guillain–Barre syndrome (GBS). Cross-reactive antibodies to ganglioside GQ1b are strongly associated with oculomotor
weakness in GBS and its variant, Miller Fisher syndrome (MFS). Antigen recognition is a crucial ﬁrst step in the induction of a cross-reactive
antibody response, and it has been shown that GQ1b-like epitopes expressed on the surface of C. jejuni are recognized by sialic acid-binding
immunoglobulin-like lectin-7 (Siglec-7). We aimed to determine the epitope speciﬁcity of C. jejuni binding to Siglec-7, and correlate the
outcome to disease symptoms in GBS and MFS patients. Using a well-deﬁned GBS/MFS-associated C. jejuni strain collection, which included
three sialic acid knockout strains, we found that Siglec-7 exclusively binds to C. jejuni strains that express terminal disialylated ganglioside
mimics. When serological and diagnostic patient records were correlated with the Siglec-7-binding properties, we observed an association
between Siglec-7 binding and the presence of anti-GQ1b antibodies in patient serum. In addition, Siglec-7 binding was associated with
oculomotor weakness in GBS and MFS patients. Lipo-oligosaccharide-speciﬁc binding of C. jejuni to Siglec-7 may be an initiating event in
immune recognition and presentation, and lead to anti-GQ1b antibody production and the development of ocular weakness in GBS or MFS.
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Abstract
Both tuberculosis cervical lymphadenitis (TCL) and oropharyngeal tularaemia (OT) have similar signs, symptoms and pathological ﬁndings.
We aimed to investigate the frequency of tularaemia antibodies in patients diagnosed with TCL. Using data from the Tuberculosis Control
Dispensaries between the years of 2008 and 2011 in Turkey, all patients diagnosed with TCL were informed about and included in the study.
Control group subjects were selected from healthy blood donors who lived in the same region. After informed consent was obtained, the
sera obtained from volunteer TCL patients and the control group were tested with a microagglutination technique for Francisella tularensis.
Antibodies to Brucella were also investigated with a tube agglutination test for cross-reactivity in sera that were seropositive for tularaemia.
Sera were obtained from a total of 1170 individuals in the TCL group and 596 in the control group from 67 of 81 provinces in Turkey.
Francisella tularensis-positive antibodies were found in 79 (6.75%) cases in the TCL group and two (0.33%) cases in the control group with a
titre of  1:80 (p < 0.01). When the presence of antibody of any titre was considered, the ratio became 8.2% (96/1170) in the TCL group
and 0.67% (4/596) in the control group (p < 0.001). For the ﬁrst time, with this study, tularaemia serology was found to be positive in a
signiﬁcant portion (6.75%) of diagnosed cases of TCL. In tularaemia endemic regions, it was concluded that tularaemia serology should be
investigated in patients suspected of having TCL.
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